One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

Back
9 January 2017, 20:21
128

Natco Pharma launches generic version of Hepatitis C drug in Nepal

Natco Pharma launches generic version of Hepatitis C drug in Nepal - picture 1

Natco Pharma launches generic version of Hepatitis C drug in Nepal

Natco Pharma has launched Velpanat-a fixed dose combination drug containing sofosbuvir(400 mg) velpatasvir (100mg) for treatment of Hepatitis C in Nepal. The medication is sold by Gilead Sciences under brand name Epclusa and is the first pan-genotypic, single tablet regimen for the treatment of Hepatitis C. Natco has signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its Hep C medicines in 101 developing countries. Velpanat is priced at Rs 25,000 equivalent for a bottle of 28 tablets in Nepal. 

Author: Marina Shegay

Share on social media